Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

cquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... 22, 2014 Research and Markets  has ... by Material, by Application, Geography - Global Analysis and ... Organic electronics, also called as polymer ... science which deals with small conductive molecules and electrically ... molecules and polymers are carbon based, made using synthetic ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... OncLive® is pleased to ... Thomas Jefferson University has joined its Strategic Alliance ... Partnership program, the Sidney Kimmel Cancer Center at ... of the Center’s cutting-edge research programs, comprehensive approach ... other health care professionals from the Sidney Kimmel ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SWX: ORIDN) today ... leading global medical device and service company.,With ... technology in its new, compact and ultra-lightweight ... the importance of monitoring CO2, has,decided to ...
... $2.0 Million -, MONTVALE, N.J., Aug. 26 ... it has secured,$2.0 million through the sale of approximately ... under its June 2007 equity financing agreement,with an investment ... Pharmaceuticals exercised its option to complete the third,and final ...
... Calif., Aug. 26 The 2008 European ... presented to,Israel-based Vascular Biogenics Ltd. for developing ... has facilitated novel advancements,in gene expression-based treatments ... VTS(TM) platform is a potent and flexible ...
Cached Biology Technology:Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 2Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 3Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 4Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 2Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 3Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 2Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 3
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... Invasive species plants, animals, and microbes introduced to regions ... tag of $1.4 trillion dollars . They are responsible for ... and an uptick in infectious diseases. Not all non-native ... the last several decades teasing apart the conditions that set ...
... 2012 In forested regions of the nation, natural regeneration ... of maintaining the desired tree species. , A study by ... and Urban Greening showed that on average, 1 in ... from natural regeneration. However, for newly established, young trees in ...
... , When you take a dip in the ocean, nuclear fuel ... Earths oceans in trace amounts of just 3 parts per billion, ... billion tons of uranium enough to potentially fuel the worlds ... the ocean as a uranium source since the 1960s, but previous ...
Cached Biology News:Losing stream in our battle to predict and prevent invasive species 2Losing stream in our battle to predict and prevent invasive species 3Natural regeneration building urban forests, altering species composition 2Natural regeneration building urban forests, altering species composition 3
... Dodeca silver stain kits are optimized ... including Bio-Rad Dodeca stainers. This silver ... of proteins in polyacrylamide gels and ... includes sensitizer concentrate, silver reagent concentrate, ...
... tubes and 96 well plates. microCLEAN is an ... a half spin DNA cleanup reagent. It can ... type of double stranded DNA, efficiently removing reaction ... or unlabelled). It is therefore ideally suited to ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
... (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides ... traces: Ca ≤ 10 mg/kg Cd ≤ 5 mg/kg ... ≤ 5 mg/kg Fe ≤ 5 mg/kg K ≤ ... mg/kg Na ≤ 50 mg/kg Ni ≤ 5 mg/kg ...
Biology Products: